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Introduction Familial hypercholesterolemia (FH) 
is one of the better‑known genetically determined 
diseases causing an accelerated development of 
atherosclerosis and early occurrence of cardio‑
vascular events.1‑3 Symptoms of coronary heart 
disease develop in more than half of men with 
heterozygous FH (HeFH) before the age of 50 
years and in 30% of women before the age of 
60 years. Cardiovascular mortality in individu‑
als with FH between 20 and 39 years of age is 
100‑times higher than in the general population.1 
Early identification of individuals with HeFH and 
effective pharmacotherapy may decrease the in‑
cidence of cardiovascular events and reduce pre‑
mature mortality.4,5 Unfortunately, the majori‑
ty of patients affected by HeFH in Poland are un‑
aware of the disease.
Epidemiology and pathogenesis FH is the most 
common monogenetic disease.1,6 Due to the auto‑
somal dominant inheritance, there are heterozy‑
gous (HeFH) and homozygous (HoFH) forms of 
the disease. HoFH occurs in 1 per 1 million live 
births, while HeFH affects on average 1 in 500 
individuals in the European countries.1 It is es‑
timated that HeFH in Poland may affect more 
than 80,000 people.
The phenotype of FH is associated with the mu‑
tation of 1 of the 3 genes: low‑density lipoprotein 
(LDL) receptor gene (approx. 1600 different muta‑
tions were described), apolipoprotein B (apoB) gene 
or proprotein convertase subtilisin/kexin type 9 
(PCSK9) gene.7‑10 Abnormal structure of LDL recep‑
tors or apoB, the ligand for LDL receptors, disturbs 
the binding of apoB containing lipoproteins to recep‑
tors. This results in impaired catabolism of LDL in 
the liver.11,12 In HeFH, the defect affects half the LDL 
receptors or half the apoB molecules. The third, re‑
cently discovered cause of FH is the presence of 
PCSK9 gene mutation, which is associated with 
the degradation activity of LDL receptors by this 
protein (gain‑of‑function mutation).10,13
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be established without genetic testing.19 If finan‑
cially feasible, it is advisable to confirm FH diag‑
nosis by genetic methods, especially in doubt‑
ful cases.
Adapted Dutch Lipid Clinic Network and Simon 
Broome Register diagnostic criteria for HeFH are 
presented in the TABLE.
Recommendations for identification of heterozygous 
familial hypercholesterolemia According to the Na‑
tional Institute for Health and Clinical Excellence 
(NICE) guidelines, coexistence of cholesterol con‑
centration over 300 mg/dl (7.8 mmol/l) with pre‑
mature cardiovascular disease in first‑degree rel‑
atives (siblings, parents, or children) is strongly 
suggestive of FH.2,20 In families with FH, the con‑
dition should be diagnosed in children and dietet‑
ic treatment initiated as soon as possible; treat‑
ment with statins should be introduced in chil‑
dren over 10 years of age.21 If HeFH is diagnosed, 
cascade screening of the family is recommend‑
ed, including both serum lipid profile and genet‑
ic testing (if possible). 1,2,22
The measurement of serum lipid concentration 
in children in families with FH is recommended 
even immediately after birth and always under 
10 years of age. Children in such families should 
undergo periodic medical examinations, includ‑
ing the measurement of body weight and blood 
pressure.21
Atherosclerosis in FH develops insidiously and 
may be advanced before any signs or symptoms 
are noted. Markers of coronary heart disease may 
be present in asymptomatic patients.23 Special‑
ist care for patients with FH makes it possible to 
confirm the diagnosis of FH in dubious cases us‑
ing a genetic method, introduce cascade testing 
in the families, and recommend lifestyle modifi‑
cations and pharmacotherapy.22,24,25 It is neces‑
sary to provide patients with a quick access to di‑
agnostic tests, which allows to detect significant 
cardiovascular disease and, if possible, cooperate 
with clinical geneticist. National programs for pa‑
tients with FH are in place worldwide: MEDPED 
in the United States, StOEH in the Netherlands, 
HEART UK – The Nation’s Cholesterol Charity in 
England, Fundacion Colesterol Familiar in Spain, 
Krajowe Centrum Diagnostyki Hipercholester‑
olemii Rodzinnej (National Centre for Diagnos‑
tics of Familial Hypercholesterolaemia) in Po‑
land, and others. It must be stressed that there 
are no separate lipid clinics in the Polish health‑
care system.
Target low‑density lipoprotein cholesterol concentra‑
tion After clinical diagnosis of FH has been es‑
tablished (a score of 5 or more), intensive treat‑
ment should be initiated without waiting for 
the results of molecular testing.2‑5
The target LDL cholesterol concentration in pa‑
tients with FH in primary prevention of coronary 
heart disease, due to a high risk, should be less 
than 2.5 mmol/l (<100 mg/dl). In patients with 
Familial hypercholesterolemia as a risk factor for cor‑
onary heart disease FH is a potent risk factor of 
coronary heart disease.14 The coexistence of ad‑
ditional risk factors, especially smoking, signifi‑
cantly accelerates the development of premature 
atherosclerosis.1,3 It is estimated that in the ma‑
jority of untreated men and women with HeFH, 
coronary heart disease manifests itself before 
the age of 60 years. FH patients are a priori as‑
signed to the high‑risk group without the need 
to use the European Society of Cardiology (ESC) 
Heart Score or Framingham algorithm to esti‑
mate the cardiovascular risk in the primary pre‑
vention. Early implemented intensive pharma‑
cotherapy before the appearance of atheroscle‑
rosis symptoms allows to achieve life expectan‑
cy among the individuals with HeFH similar to 
the general population.15‑17
Heterozygous familial hypercholesterolemia diag‑
nostic criteria FH is diagnosed on the basis of 
the Dutch Lipid Network criteria adopted in Ge‑
neva in 1998 by the World Health Organization.1 
The criteria were also adopted by the ESC and Eu‑
ropean Atherosclerosis Society (EAS) in “ESC/EAS 
Guidelines for the Management of Dyslipidae‑
mias” 2011.3 The clinical criteria of FH include 
high plasma levels of LDL cholesterol, presence 
of arcus cornealis and tendinous xanthomas, pre‑
mature cardiovascular disease, and positive fam‑
ily history of hypercholesterolemia and prema‑
ture cardiovascular disease. 6,18,19 The presence of 
xanthomas on the extensor tendons of the hands 
and on the Achilles tendon is pathognomonic for 
the diagnosis of FH. The lower age limit for pre‑
mature cardiovascular disease is considered to be 
55 years in men and 60 years in women.
The basic biochemical parameter in FH di‑
agnosis is the high level of LDL cholesterol (in 
heterozygotes usually from 2 to 3 times higher 
than the population average), usually with a nor‑
mal level of triglycerides.1,16 Total cholesterol lev‑
el in heterozygotes is usually between 290 and 
500 mg/dl (7.5–12.9 mmol/l), and in homozygotes 
between 600 and 1000 mg/dl (15.5–25.8 mmol/
l).1 Lipid profile in patients with FH may resemble 
that obtained in secondary hypercholesterolemia, 
e.g., in the course of hypothyroidism, diabetes, 
nephrotic syndrome, as a result of long‑term 
therapy with corticosteroids, progestogens, or 
protease inhibitors used to treat human immu‑
nodeficiency virus infection.3 Sometimes, an in‑
creased level of triglycerides secondary to, for 
example, diabetes, obesity, or excessive alcohol 
consumption occurs in typical FH. In such cas‑
es, any doubts about the diagnosis of FH can be 
clarified by obtaining a lipid profile of relatives 
and by genetic testing.19
The Dutch Lipid Network and Simon Broome 
Register criteria adapted to Polish conditions 
(TABLE) may be helpful in the office setting. They 
allow to make a certain, probable, or possible di‑
agnosis of FH in the clinical setting.1‑3 It should 
be noted that the clinical diagnosis of FH might 
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smoking, physical activity (at least 30 minutes of 
exercise for a minimum of 5 days per week – brisk 
walking, running, or cycling), arterial blood pres‑
sure <140/90 mmHg, body mass index <25 kg/m2, 
avoidance (or treatment) of central obesity, and 
cholesterol‑lowering diet.1‑3 However, in patients 
with FH even an appropriate diet would not ade‑
quately lower the LDL cholesterol concentration, 
and the introduction of pharmacological treat‑
ment is necessary. In FH, the treatment of choice 
are statins at the maximum tolerated dose.3,18 Re‑
sponse to treatment with statins is highly indi‑
vidually variable (concentration reduction by 10% 
to 70%) due to (among other factors) the type of 
the LDL receptor mutation. Although statins are 
currently the most potent class of hypolipemic 
medications available, in many patients with 
FH (as mentioned above) the target LDL cho‑
lesterol concentrations cannot be achieved with 
monotherapy.2,3,18,25 In such cases, the goal of 
treatment should be the maximum LDL cholester‑
ol reduction attainable with an appropriate combi‑
nation treatment at tolerated doses: a statin with 
a cholesterol absorption inhibitor (ezetimibe), 
a bile acid‑binding agent (anion‑exchange resin), 
or nicotinic acid.3 In the case of statin intolerance, 
ezetimibe, an anion‑exchange resin or nicotinic 
acid may be used in monotherapy. A modern anion‑ 
‑exchange resin (colesevelam) and nicotinic acid 
are not yet available in Poland. The position con‑
cerning treatment of children and adolescents will 
be presented in a separate paper.
Women with FH who plan pregnancy or are 
pregnant or breastfeeding should not receive sta‑
tins.26 In women of childbearing potential, the use 
of highly effective contraceptive methods is rec‑
ommended; oral hormonal contraceptives should 
be avoided, if possible. Women should be instruct‑
ed to stop hypolipemic treatment 3 months prior 
to the planned pregnancy.26 The only hypolipemic 
treatment admissible in pregnancy is the use of 
an agent preventing the enterohepatic recircula‑
tion of bile acids (e.g., colesevelam).
A new class of medications, PCSK9 inhibi‑
tors, may offer a promising treatment option in 
FH, and the results of studies concerning these 
drugs (published in 2012) indicated that the hy‑
polipemic effect of the investigated monoclonal 
antibodies was convincing.27‑32
Conclusions HeFH is a relatively common lip‑
id disorder, usually remaining undiagnosed and 
untreated. A very high risk of cardiovascular dis‑
eases and a shortened lifespan in patients with 
this condition require early diagnosis and inten‑
sive treatment.
Note The position paper has been officially en‑
dorsed by the Cardiovascular Working Group of 
the Polish Cardiac Society.
Conflict of interest K.J.F.: honoraria for lectures/
membership in advisory boards (Adamed, Astra‑
Zeneca, BerlinChemie, Bristol‑Myers Squibb, Egis, 
concomitant cardiovascular disease the risk is very 
high and the goal of treatment is LDL cholesterol 
concentration below 1.8 mmol/l (<70 mg/dl).2,5 
If this is not possible, reduction by at least 50% 
from baseline is recommended. This goal may be 
difficult to achieve with statins alone; therefore, 
combination pharmacotherapy is often neces‑
sary.3 In the ESC/EAS guidelines on the manage‑
ment of dyslipidemia (2011) the experts stated: 
“if the target level is not reached, statin combina‑
tion with cholesterol absorption inhibitor or bile 
acid sequestrant or nicotinic acid may be consid‑
ered”. In Poland, only the first option is currently 
feasible, i.e., the addition of ezetimibe after an at‑
tempt at treatment with the maximum tolerated 
dose of a statin, is feasible.
In our opinion, a score of 5 or more should be 
considered sufficient justification for the intro‑
duction of the recommended treatment of FH, re‑
imbursed from the public means in Poland.
Therapeutic management of heterozygous familial 
hypercholesterolemia The most important ob‑
jective of treatment in patients with FH is to re‑
duce premature cardiovascular mortality as well 
as the incidence of myocardial infarction and 
the need for revascularization. Lifestyle chang‑
es are necessary to eliminate additional cardio‑
vascular risk factors.3 Recommendations for pa‑
tients with FH include absolute abstinence from 
TABLE Heterozygous familial hypercholesterolemia diagnostic criteria – score; 
adaptation of the Dutch Lipid Clinic Network (World Health Organization) and Simon 
Broome Register scale
clinical history
premature coronary heart disease (men <55 years, women <60 years) 2
premature cerebral or peripheral vascular disease 1
family history
first-degree relatives with premature coronary or vascular disease 1
first-degree relatives with LDL above 190 mg/dl 1
first-degree relatives with tendon xanthomata and/or corneal arcus 2
children aged less than 18 years with LDL cholesterol above 155 mg/dl 2
physical examination
tendon xanthomata 6
corneal arcus below the age of 45 years 4
laboratory analysis
LDL cholesterol
>8.5 mmol/l (330 mg/dl) 8
6.5–8.4 mmol/l (250–329 mg/dl) 5
5.0–6.4 mmol/l (190–249 mg/dl) 3
4.0–4.9 mmol/l (155–189 mg/dl) 1
genetic testing
mutation of LDL receptor gene 8
diagnosis of familial hypercholesterolemia
definite >8
probable 6–8
possible 3–5
no diagnosis <3
Abbreviations: LDL – low-density lipoprotein
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